BRCA1 and neoplasm: Eighty percent of breast cancer patients with a BRCA1 mutation are diagnosed as triple negative,94 making up to 10–30% of all TNBC cases.35 In comparison with wild type patients, those with BRCA1 mutations have been shown to have higher tumor specific neoantigens which stimulate the recruitment of T cells into the TME.95 Furthermore, 60–69% of TNBC patients who do not have a BRCA mutation, still have a similar phenotype, known as “BRCAness”.41 Patients with either BRCA1/2 mutations or “BRCAness” are more immunogenic than TNBC tumors without these genetic mutations and phenotype.41